Screener
UroGen Pharma URGN Total Liabilities
Total Liabilities at other companies
Other financials
Where this comes from
Reported directly by UroGen Pharma in its filing.
Tagged under the XBRL concept us-gaap:Liabilities.
The source filing: UroGen Pharma’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 8:05 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001437749-26-025794
| Line item | June 30, 2026 | December 31, 2025 |
|---|---|---|
| Finance long-term lease liabilities | 2,939 | 3,475 |
| Operating long-term lease liabilities | 2,360 | 2,647 |
| Uncertain tax positions liability | 3,903 | 3,903 |
| Total liabilities | 384,986 | 305,929 |
| Commitments and contingencies (Note 19) | ||
| Shareholders' deficit: | ||
| Ordinary shares, NIS 0.01 par value, 100,000,000 shares authorized at June 30, 2026 and December 31, 2025; 48,869,530 and 48,350,272 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively | 135 | 133 |
| Additional paid-in capital | 865,112 | 854,090 |
Item 1. Financial Statements.
FAQ
- What is UroGen Pharma's total liabilities?
- UroGen Pharma (URGN) reported total liabilities of $384.99M in Q2 2026.
- How has UroGen Pharma's total liabilities changed year-over-year?
- UroGen Pharma's total liabilities increased by 27.4% year-over-year, from $302.09M to $384.99M.
- What is the long-term trend for UroGen Pharma's total liabilities?
- Over 5 years (2020 to 2025), UroGen Pharma's total liabilities has grown at a 64.2% compound annual growth rate (CAGR), from $25.65M to $305.93M.
- What does total liabilities mean?
- The sum of all current and non-current obligations — everything the company owes to creditors, employees, governments, and other stakeholders.
Ask your AI about UroGen Pharma's total liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude